| 1 | Efficacy of 3D-TSE sequence-based radiosurgery in prolonging time to distant intracranial failure: A session-wise analysis in a histology-diverse patient cohort | 1.0 | 4 | Citations (PDF) |
| 2 | Routine machine quality assurance tests for a self‐shielded gyroscopic radiosurgery system | 2.1 | 2 | Citations (PDF) |
| 3 | Evolving Trends and Patterns of Utilization of Magnetic Resonance-Guided Radiotherapy at a Single Institution, 2018–2024 | 3.8 | 2 | Citations (PDF) |
| 4 | Future Directions in the Treatment of Low-Grade Gliomas | 1.8 | 0 | Citations (PDF) |
| 5 | The role of upfront radiation therapy for brain metastases in the era of CNS-active systemic therapies: a narrative review of clinical trial design and lessons learned | 2.5 | 0 | Citations (PDF) |
| 6 | Proton Craniospinal Irradiation for Patients with Solid Tumor Leptomeningeal Disease: Real-World Feasibility, Toxicity, and Outcome Analysis | 3.8 | 3 | Citations (PDF) |
| 7 | Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Infradiaphragmatic Oligometastatic Disease: Disrupting the One-Size-Fits-All Paradigm | 1.5 | 2 | Citations (PDF) |
| 8 | Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients | 2.5 | 2 | Citations (PDF) |
| 9 | Temporospatial tumor dynamic changes in glioblastoma during radiotherapy | 2.5 | 1 | Citations (PDF) |
| 10 | Analysis of Medicare Reimbursement Trends in Medical and Radiation Oncology | 2.7 | 0 | Citations (PDF) |
| 11 | Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases | 2.5 | 2 | Citations (PDF) |
| 12 | Quantifying and addressing self-defined needs in cancer patients | 2.2 | 0 | Citations (PDF) |
| 13 | The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma | 2.0 | 0 | Citations (PDF) |
| 14 | Commissioning Intracranial Stereotactic Radiosurgery for a Magnetic Resonance-Guided Radiation Therapy (MRgRT) System: MR-RT Localization and Dosimetric End-to-End Validation | 1.5 | 4 | Citations (PDF) |
| 15 | Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer | 0.9 | 1 | Citations (PDF) |
| 16 | Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001 | 1.0 | 8 | Citations (PDF) |
| 17 | The First Report of Using Low-Field MRI-Guided Radiation Therapy in a Patient With a Cochlear Implant | 1.3 | 1 | Citations (PDF) |
| 18 | Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012 to 2021) From the National Association for Proton Therapy | 1.5 | 45 | Citations (PDF) |
| 19 | In Reply to Halperin | 1.5 | 0 | Citations (PDF) |
| 20 | In Regard to Trifiletti et al. | 1.5 | 1 | Citations (PDF) |
| 21 | Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors | 2.0 | 5 | Citations (PDF) |
| 22 | Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001 | 4.6 | 1 | Citations (PDF) |
| 23 | Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort | 1.0 | 9 | Citations (PDF) |
| 24 | Clinical application of an institutional fractionated stereotactic radiosurgery (FSRS) program for brain metastases delivered with MRIdianⓇ BrainTx™ | 0.9 | 2 | Citations (PDF) |
| 25 | An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice | 2.7 | 12 | Citations (PDF) |
| 26 | Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease | 0.9 | 5 | Citations (PDF) |
| 27 | Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice | 2.5 | 1 | Citations (PDF) |
| 28 | Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era | 16.9 | 8 | Citations (PDF) |
| 29 | Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis | 2.5 | 8 | Citations (PDF) |
| 30 | Quality assurance of an established online adaptive radiotherapy program: patch and software upgrade | 2.6 | 4 | Citations (PDF) |
| 31 | The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas | 1.0 | 8 | Citations (PDF) |
| 32 | Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy for Painful Spinal Metastases: A Comparative Analysis of Randomized Trials and Practical Considerations | 2.7 | 4 | Citations (PDF) |
| 33 | Case report: Intrafraction dose-guided tracking for gastrointestinal organ-at-risk isotoxicity delivery on an MR-guided radiotherapy system | 2.6 | 1 | Citations (PDF) |
| 34 | TREATMENT TRENDS OF TUMOR SITES AND CLINICAL COMPLEXITY FROM UNITED STATES SURVEY DATA | 1.9 | 0 | Citations (PDF) |
| 35 | BRAIN SUBSTRUCTURE ATROPHY IS ASSOCIATED WITH RADIATION DOSE AND NEUROCOGNITIVE OUTCOMES TWO YEARS FOLLOWING PROTON THERAPY: A PROSPECTIVE LONGITUDINAL TRIAL | 1.9 | 0 | Citations (PDF) |
| 36 | CHARACTERIZATION OF LET DISTRIBUTIONS FOR BRAIN TUMOR PATIENTS WITH ADJACENT CRITICAL OARS TREATED WITH INTENSITY MODULATED PROTON THERAPY | 1.9 | 0 | Citations (PDF) |
| 37 | THE BEST OF BOTH WORLDS: COMBINED PROTON-PHOTON RADIOTHERAPY FOR DIFFICULT-TO-TREAT SKULL BASE AND SPINE TUMORS | 1.9 | 0 | Citations (PDF) |
| 38 | POST-RADIOTHERAPY NEUROCOGNITIVE FUNCTION EVALUATION IN PRIMARY BRAIN TUMOR PATIENTS ON A PROSPECTIVE OBSERVATIONAL STUDY UTILIZING A MULTI-DIMENSIONAL APP-BASED ASSESSMENT TOOL | 1.9 | 0 | Citations (PDF) |
| 39 | Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities | 1.1 | 6 | Citations (PDF) |
| 40 | Radiotherapeutic advances in the management of glioblastoma | 2.5 | 2 | Citations (PDF) |
| 41 | PO0111 | 1.1 | 0 | Citations (PDF) |
| 42 | Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies | 3.4 | 0 | Citations (PDF) |
| 43 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial | 1.0 | 140 | Citations (PDF) |
| 44 | Racial disparities in clinical presentation, surgical procedures, and hospital outcomes among patients with hepatocellular carcinoma in the United States | 2.0 | 9 | Citations (PDF) |
| 45 | Rethinking classification and categorization of resection extent and its impact on patient survival in glioblastoma: Was Walter Dandy ahead of his time? | 1.0 | 2 | Citations (PDF) |
| 46 | Dosimetric Impact of Lesion Number, Size, and Volume on Mean Brain Dose with Stereotactic Radiosurgery for Multiple Brain Metastases | 3.8 | 12 | Citations (PDF) |
| 47 | Developing an AI-assisted planning pipeline for hippocampal avoidance whole brain radiotherapy | 2.0 | 14 | Citations (PDF) |
| 48 | Modern Meningioma Methods: Molecular Diagnostics and High Dose Protons | 1.5 | 1 | Citations (PDF) |
| 49 | OptImal Gamma kNife lIghTnIng sOlutioN (IGNITION) score to characterize the solution space of the Gamma Knife FIP optimizer for stereotactic radiosurgery | 2.1 | 1 | Citations (PDF) |
| 50 | The Rationale for Radiation Therapy in Alzheimer's Disease | 2.1 | 10 | Citations (PDF) |
| 51 | Low-Dose Whole Brain Radiation Therapy for Alzheimer's Dementia: Results From a Pilot Trial in Humans | 1.5 | 14 | Citations (PDF) |
| 52 | Treatment of glioblastoma using MRIdian® A3i BrainTx™: Imaging and treatment workflow demonstration | 0.9 | 12 | Citations (PDF) |
| 53 | Evaluating the intracranial activity of adagrasib | 2.0 | 1 | Citations (PDF) |
| 54 | Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas | 0.9 | 2 | Citations (PDF) |
| 55 | Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer | 0.9 | 3 | Citations (PDF) |
| 56 | A study on inter‐planner plan quality variability using a manual planning‐ or Lightning dose optimizer‐approach for single brain lesions treated with the Gamma Knife® Icon™ | 2.1 | 5 | Citations (PDF) |
| 57 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways | 25.2 | 138 | Citations (PDF) |
| 58 | Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer | 2.0 | 16 | Citations (PDF) |
| 59 | Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience | 1.1 | 12 | Citations (PDF) |
| 60 | National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities | 27.4 | 35 | Citations (PDF) |
| 61 | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults | 16.9 | 394 | Citations (PDF) |
| 62 | Comparing Changes in Medicare Reimbursement for Radiation Oncology and Medical Oncology (2010-2020) | 1.5 | 0 | Citations (PDF) |
| 63 | A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups | 27.4 | 57 | Citations (PDF) |
| 64 | RTID-06. THE PIVOTAL METIS (EF-25) STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING RADIOSURGERY | 1.0 | 0 | Citations (PDF) |
| 65 | CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL | 1.0 | 0 | Citations (PDF) |
| 66 | Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma | 6.8 | 40 | Citations (PDF) |
| 67 | Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement | 6.8 | 151 | Citations (PDF) |
| 68 | Systematic evaluation and plan quality assessment of the Leksell® gamma knife® lightning dose optimizer | 0.9 | 19 | Citations (PDF) |
| 69 | Dose-Escalated Magnetic Resonance Image–Guided Abdominopelvic Reirradiation With Continuous Intrafraction Visualization, Soft Tissue Tracking, and Automatic Beam Gating | 1.3 | 14 | Citations (PDF) |
| 70 | CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy | 2.0 | 27 | Citations (PDF) |
| 71 | Relationship between insurance status and interhospital transfers among cancer patients in the United States | 2.9 | 4 | Citations (PDF) |
| 72 | Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases | 2.6 | 16 | Citations (PDF) |
| 73 | Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors | 1.5 | 104 | Citations (PDF) |
| 74 | Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases | 3.4 | 19 | Citations (PDF) |
| 75 | Hospitalization rates from radiotherapy complications in the United States | 3.4 | 15 | Citations (PDF) |
| 76 | Evaluation of a prospective radiation oncology departmental team review process using standardized simulation directives | 2.0 | 3 | Citations (PDF) |
| 77 | Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data | 3.8 | 15 | Citations (PDF) |
| 78 | Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions | 1.0 | 156 | Citations (PDF) |
| 79 | Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases | 1.3 | 7 | Citations (PDF) |
| 80 | Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis | 3.0 | 18 | Citations (PDF) |
| 81 | RONC-13. Change in hippocampus volume as a function of radiation dose: Results from a prospective trial with standardized imaging and morphometric evaluation | 1.0 | 1 | Citations (PDF) |
| 82 | Dedicated isotropic 3-D T1 SPACE sequence imaging for radiosurgery planning improves brain metastases detection and reduces the risk of intracranial relapse | 2.0 | 15 | Citations (PDF) |
| 83 | Optimizing the radiotherapy treatment planning process for glioblastoma | 0.9 | 1 | Citations (PDF) |
| 84 | Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results | 3.8 | 8 | Citations (PDF) |
| 85 | Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors | 16.9 | 85 | Citations (PDF) |
| 86 | Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife® Icon™ Stereotactic Radiosurgery for Brain Metastases | 3.8 | 16 | Citations (PDF) |
| 87 | Deep Learning-Based Automatic Detection of Brain Metastases in Heterogenous Multi-Institutional Magnetic Resonance Imaging Sets: An Exploratory Analysis of NRG-CC001 | 1.5 | 17 | Citations (PDF) |
| 88 | Access to Radiation Therapy: From Local to Global and Equality to Equity | 2.1 | 31 | Citations (PDF) |
| 89 | CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS | 1.0 | 7 | Citations (PDF) |
| 90 | Does hippocampal atrophy correlate with patient-reported adaptive function one year following radiotherapy? Results from a prospective trial | 1.5 | 0 | Citations (PDF) |
| 91 | Prevalence and Inpatient Hospital Outcomes of Malignancy-Related Ascites in the United States | 1.6 | 14 | Citations (PDF) |
| 92 | Can proton therapy reduce radiation-related lymphopenia in glioblastoma? | 1.0 | 5 | Citations (PDF) |
| 93 | Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825) | 1.0 | 39 | Citations (PDF) |
| 94 | Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance | 0.9 | 25 | Citations (PDF) |
| 95 | Case report of visual biofeedback-driven, magnetic resonance-guided single-fraction SABR in breath hold for early stage non–small-cell lung cancer | 0.9 | 10 | Citations (PDF) |
| 96 | Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group | 1.0 | 117 | Citations (PDF) |
| 97 | Novel Radiation Approaches | 1.4 | 8 | Citations (PDF) |
| 98 | Regression of Intracranial Meningiomas Following Treatment with Cabozantinib | 3.0 | 8 | Citations (PDF) |
| 99 | Hospitalization rates for complications due to systemic therapy in the United States | 3.4 | 18 | Citations (PDF) |
| 100 | Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes | 1.3 | 5 | Citations (PDF) |
| 101 | Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy | 3.8 | 11 | Citations (PDF) |
| 102 | Effect of a physician led education invention on colon cancer screening at underserved clinics in Georgia | 2.1 | 3 | Citations (PDF) |
| 103 | Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report | 0.9 | 9 | Citations (PDF) |
| 104 | Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models? | 2.0 | 7 | Citations (PDF) |
| 105 | Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases | 3.8 | 41 | Citations (PDF) |
| 106 | Systematic review of combinations of targeted or immunotherapy in advanced solid tumors 2021, 9, e002459 | | 75 | Citations (PDF) |
| 107 | Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery | 0.9 | 6 | Citations (PDF) |
| 108 | Effect of Postoperative Radiation Therapy Timing on Survival in Pediatric and Young Adult Ependymoma | 1.3 | 2 | Citations (PDF) |
| 109 | Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases | 0.9 | 7 | Citations (PDF) |
| 110 | RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis | 0.9 | 0 | Citations (PDF) |
| 111 | OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance | 0.9 | 0 | Citations (PDF) |
| 112 | Endoscopic ultrasound guided portal‐systemic pressure gradient measurement to determine candidacy for kidney transplant alone versus combined liver kidney transplant in patients with advanced fibrosis or cirrhosis | 2.0 | 4 | Citations (PDF) |
| 113 | A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas | 2.5 | 11 | Citations (PDF) |
| 114 | Establishing the Aortic Maximum Tolerated Dose (MTD) for Ablative 5-Fraction Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) | 1.5 | 0 | Citations (PDF) |
| 115 | Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance | 2.4 | 15 | Citations (PDF) |
| 116 | A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation | 2.7 | 3 | Citations (PDF) |
| 117 | Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 | 2.5 | 13 | Citations (PDF) |
| 118 | Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis | 0.9 | 14 | Citations (PDF) |
| 119 | Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States | 3.4 | 8 | Citations (PDF) |
| 120 | High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539 | 1.5 | 181 | Citations (PDF) |
| 121 | 30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL | 0.9 | 0 | Citations (PDF) |
| 122 | 33. SYSTEMATIC REVIEW AND META-ANALYSIS OF BREAST CANCER BRAIN METASTASIS AND PRIMARY TUMOR RECEPTOR EXPRESSION DISCORDANCE | 0.9 | 1 | Citations (PDF) |
| 123 | Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02 | 0.9 | 12 | Citations (PDF) |
| 124 | Radiotherapy innovations to optimize brain metastases control | 1.0 | 0 | Citations (PDF) |
| 125 | Inpatient Palliative Care Use Among Critically III Brain Metastasis Patients in the United States | 1.3 | 6 | Citations (PDF) |
| 126 | Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016 | 1.3 | 1 | Citations (PDF) |
| 127 | Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient | 16.9 | 417 | Citations (PDF) |
| 128 | Stereotactic Body Radiotherapy of Painful Osseous Metastases: A Correlation Meta-Analysis | 1.5 | 0 | Citations (PDF) |
| 129 | A Novel Pre-plan Technique for On-table Adaptation of Pancreatic Stereotactic MR-guided Online Adaptive Radiotherapy | 1.5 | 1 | Citations (PDF) |
| 130 | Effectiveness of Radiofrequency Ablation in the Treatment of Painful Osseous Metastases: A Correlation Meta-Analysis with Machine Learning Cluster Identification | 1.1 | 19 | Citations (PDF) |
| 131 | A risk model for prediction of 30-day readmission rates after surgical treatment for colon cancer | 1.8 | 3 | Citations (PDF) |
| 132 | Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes | 1.0 | 2 | Citations (PDF) |
| 133 | NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma | 4.0 | 40 | Citations (PDF) |
| 134 | Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia | 2.6 | 28 | Citations (PDF) |
| 135 | Early imaging marker of progressing glioblastoma: a window of opportunity | 2.5 | 5 | Citations (PDF) |
| 136 | Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival | 1.0 | 74 | Citations (PDF) |
| 137 | Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today | 1.5 | 134 | Citations (PDF) |
| 138 | Biological activity of weekly ONC201 in adult recurrent glioblastoma patients | 1.0 | 82 | Citations (PDF) |
| 139 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424 | 1.5 | 51 | Citations (PDF) |
| 140 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions | 1.0 | 1,018 | Citations (PDF) |
| 141 | Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition | 9.2 | 90 | Citations (PDF) |
| 142 | Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients | 1.0 | 29 | Citations (PDF) |
| 143 | Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure | 2.1 | 17 | Citations (PDF) |
| 144 | Transrectal Endoscopic Ultrasound-Guided Drainage of a Tubo-Ovarian Abscess Via a Lumen-Apposing Metal Stent | 0.5 | 4 | Citations (PDF) |
| 145 | RADT-31. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016 | 1.0 | 0 | Citations (PDF) |
| 146 | RTID-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS TRIAL | 1.0 | 0 | Citations (PDF) |
| 147 | RTID-08. A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (ndGBM OR rGBM) | 1.0 | 0 | Citations (PDF) |
| 148 | Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review | 2.0 | 61 | Citations (PDF) |
| 149 | Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933 | 1.3 | 27 | Citations (PDF) |
| 150 | Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA) | 0.9 | 31 | Citations (PDF) |
| 151 | Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma | 2.5 | 52 | Citations (PDF) |
| 152 | TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL | 0.9 | 0 | Citations (PDF) |
| 153 | TRLS-09. RTOG1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY / STEREOTACTIC RADIOSURGERY IN COMBINATION WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER | 0.9 | 0 | Citations (PDF) |
| 154 | The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525 | 0.9 | 8 | Citations (PDF) |
| 155 | Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 | 2.5 | 178 | Citations (PDF) |
| 156 | Letter: When Less is More: Dexamethasone Dosing for Brain Tumors | 2.0 | 29 | Citations (PDF) |
| 157 | Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities | 1.6 | 33 | Citations (PDF) |
| 158 | The Complexity of Managing Large Brain Metastasis | 1.5 | 8 | Citations (PDF) |
| 159 | Updates in the management of intradural spinal cord tumors: a radiation oncology focus | 1.0 | 42 | Citations (PDF) |
| 160 | Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis | 1.1 | 8 | Citations (PDF) |
| 161 | NRG brain tumor specialists consensus guidelines for glioblastoma contouring | 2.5 | 108 | Citations (PDF) |
| 162 | Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress? | 4.0 | 13 | Citations (PDF) |
| 163 | Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous | 2.7 | 28 | Citations (PDF) |
| 164 | Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420 | 1.5 | 10 | Citations (PDF) |
| 165 | INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS | 1.0 | 30 | Citations (PDF) |
| 166 | MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges | 1.0 | 285 | Citations (PDF) |
| 167 | Low-Grade Glioma Radiotherapy Treatment and Trials | 1.4 | 78 | Citations (PDF) |
| 168 | Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes | 2.0 | 10 | Citations (PDF) |
| 169 | Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database | 1.0 | 44 | Citations (PDF) |
| 170 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 | 1.0 | 136 | Citations (PDF) |
| 171 | Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations | 2.1 | 22 | Citations (PDF) |
| 172 | Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group | 27.4 | 54 | Citations (PDF) |
| 173 | Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis | 1.0 | 8 | Citations (PDF) |
| 174 | Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order | 1.5 | 3 | Citations (PDF) |
| 175 | Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms | 5.0 | 60 | Citations (PDF) |
| 176 | Preradiation Chemotherapy for Adult High-risk Medulloblastoma | 1.3 | 24 | Citations (PDF) |
| 177 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525 | 1.5 | 65 | Citations (PDF) |
| 178 | The Evolving Role of Tumor Treating Fields in Managing Glioblastoma | 1.3 | 69 | Citations (PDF) |
| 179 | Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer | 1.4 | 34 | Citations (PDF) |
| 180 | P05.83 Tumor Treating Fields and radiosurgery for supra- and/or infratentorial brain metastases (1–10) from NSCLC in the phase 3 METIS study | 1.0 | 0 | Citations (PDF) |
| 181 | ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS | 1.0 | 3 | Citations (PDF) |
| 182 | RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY | 1.0 | 0 | Citations (PDF) |
| 183 | Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001 | 1.5 | 49 | Citations (PDF) |
| 184 | Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred? | 16.9 | 0 | Citations (PDF) |
| 185 | What is the evidence for the clinical value of SBRT in cancer of the cervix? | 1.5 | 17 | Citations (PDF) |
| 186 | Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases | 1.5 | 25 | Citations (PDF) |
| 187 | Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool | 1.0 | 63 | Citations (PDF) |
| 188 | Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study | 2.5 | 17 | Citations (PDF) |
| 189 | Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus | 2.5 | 23 | Citations (PDF) |
| 190 | Recent advances in managing brain metastasis | 0.5 | 93 | Citations (PDF) |
| 191 | Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 | 1.0 | 44 | Citations (PDF) |
| 192 | An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 | 1.0 | 122 | Citations (PDF) |
| 193 | Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era | 14.4 | 96 | Citations (PDF) |
| 194 | Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer | 2.0 | 22 | Citations (PDF) |
| 195 | Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients | 5.0 | 101 | Citations (PDF) |
| 196 | A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients | 1.5 | 35 | Citations (PDF) |
| 197 | The role of radiation in treating glioblastoma: here to stay | 2.5 | 35 | Citations (PDF) |
| 198 | The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases | 1.5 | 63 | Citations (PDF) |
| 199 | Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease | 2.1 | 13 | Citations (PDF) |
| 200 | Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer | 2.0 | 100 | Citations (PDF) |
| 201 | The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria | 1.0 | 210 | Citations (PDF) |
| 202 | A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas | 2.5 | 33 | Citations (PDF) |
| 203 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG | 1.0 | 128 | Citations (PDF) |
| 204 | Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline | 16.9 | 143 | Citations (PDF) |
| 205 | Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA) | 1.5 | 201 | Citations (PDF) |
| 206 | Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation | 2.5 | 25 | Citations (PDF) |
| 207 | Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer | 1.5 | 89 | Citations (PDF) |
| 208 | Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials | 1.5 | 65 | Citations (PDF) |
| 209 | OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas | 1.0 | 3 | Citations (PDF) |
| 210 | Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 | 2.5 | 29 | Citations (PDF) |
| 211 | Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer | 2.1 | 14 | Citations (PDF) |
| 212 | Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine | 4.5 | 20 | Citations (PDF) |
| 213 | Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review | 1.4 | 61 | Citations (PDF) |
| 214 | ACTR-38. NRG/RTOG 1119: PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868) | 1.0 | 0 | Citations (PDF) |
| 215 | BMET-03. METIS: A PHASE III STUDY OF RADIOSURGERY WITH TTFIELDS FOR 1-10 BRAIN METASTASES FROM NSCLC | 1.0 | 0 | Citations (PDF) |
| 216 | Clinical ramifications of “genomic staging” of low-grade gliomas | 2.5 | 14 | Citations (PDF) |
| 217 | Updates in the management of brain metastases | 1.0 | 255 | Citations (PDF) |
| 218 | A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy | 4.0 | 199 | Citations (PDF) |
| 219 | Stereotactic Radiosurgery for Treatment of Brain Metastases | 2.9 | 51 | Citations (PDF) |
| 220 | Proton therapy for paediatric CNS tumours — improving treatment-related outcomes | 28.6 | 63 | Citations (PDF) |
| 221 | Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer | 2.3 | 62 | Citations (PDF) |
| 222 | Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma | 34.6 | 997 | Citations (PDF) |
| 223 | Neural stem cells, the subventricular zone and radiotherapy: implications for treating glioblastoma | 2.5 | 34 | Citations (PDF) |
| 224 | The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases | 1.5 | 94 | Citations (PDF) |
| 225 | EP-1191: Pattern of metastasis in different molecular sub-types of locally advanced carcinoma breast | 2.0 | 0 | Citations (PDF) |
| 226 | An Independently Validated Nomogram for Individualized Estimation of Survival Among Patients With Newly Diagnosed Glioblastoma: NRG Oncology/RTOG 0525 and 0825 | 1.5 | 5 | Citations (PDF) |
| 227 | Proton radiotherapy for gynecologic neoplasms | 1.8 | 26 | Citations (PDF) |
| 228 | Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients | 1.8 | 25 | Citations (PDF) |
| 229 | Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma—An Easy Question Turned Difficult: Treat the Scan or the Patient? | 16.9 | 6 | Citations (PDF) |
| 230 | Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813 | 1.5 | 1 | Citations (PDF) |
| 231 | Glioblastoma: Radiation treatment margins, how small is large enough? | 2.7 | 47 | Citations (PDF) |
| 232 | International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties | 1.5 | 9 | Citations (PDF) |
| 233 | Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma | 1.6 | 74 | Citations (PDF) |
| 234 | Pathologic deposition of non-amyloid immunoglobulin in the brain leading to mass effect and neurological deficits | 1.6 | 4 | Citations (PDF) |
| 235 | Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539 | 1.0 | 116 | Citations (PDF) |
| 236 | NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma | 2.5 | 65 | Citations (PDF) |
| 237 | Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study | 2.5 | 88 | Citations (PDF) |
| 238 | SU-F-R-04: Radiomics for Survival Prediction in Glioblastoma (GBM) | 3.1 | 6 | Citations (PDF) |
| 239 | Anteriorly Oriented Beam Arrangements with Daily in Vivo Range Verification for Proton Therapy of Prostate Cancer: Rectal Toxicity Rates | 1.9 | 7 | Citations (PDF) |
| 240 | Free Breathing versus Breath-Hold Scanning Beam Proton Therapy and Cardiac Sparing in Breast Cancer | 1.9 | 15 | Citations (PDF) |
| 241 | Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine | 4.5 | 4 | Citations (PDF) |
| 242 | Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review | 1.9 | 0 | Citations (PDF) |
| 243 | SU-F-T-188: A Robust Treatment Planning Technique for Proton Pencil Beam Scanning Cranial Spinal Irradiation | 3.1 | 0 | Citations (PDF) |
| 244 | RTRB-05DEFINING THE ROLE OF PROPHYLACTIC CRANIAL IRRADIATION IN NSCLC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE WORLD'S LITERATURE | 1.0 | 2 | Citations (PDF) |
| 245 | ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA | 1.0 | 2 | Citations (PDF) |
| 246 | NCO-14PRE-TREATMENT HIPPOCAMPAL VOLUME PREDICTS NEUROCOGNITIVE FUNCTION (NCF) FOR PATIENTS TREATED WITH HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIOTHERAPY (HA-WBRT) FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0933 | 1.0 | 0 | Citations (PDF) |
| 247 | Proton Beam Therapy Basics | 2.3 | 1 | Citations (PDF) |
| 248 | BMET-20RTOG1119 PHASE II RANDOMIZED STUDY OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT LAPATINIB IN PATIENTS WITH BRAIN METASTASIS FROM Her2-POSITIVE BREAST CANCER: A COLLABORATIVE STUDY OF NRG AND KROG (NCT01622868) | 1.0 | 0 | Citations (PDF) |
| 249 | RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825 | 1.0 | 0 | Citations (PDF) |
| 250 | OP02ADOLESCENT/YOUNG ADULT MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENT STRATEGY | 1.0 | 0 | Citations (PDF) |
| 251 | ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG) | 1.0 | 4 | Citations (PDF) |
| 252 | Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence? | 4.5 | 14 | Citations (PDF) |
| 253 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients | 2.8 | 52 | Citations (PDF) |
| 254 | Response assessment criteria for brain metastases: proposal from the RANO group | 27.4 | 986 | Citations (PDF) |
| 255 | ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA | 1.0 | 1 | Citations (PDF) |
| 256 | ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525 | 1.0 | 0 | Citations (PDF) |
| 257 | ATCT-08THE IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC AND NRG ONCOLOGY/RTOG | 1.0 | 3 | Citations (PDF) |
| 258 | ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA | 1.0 | 4 | Citations (PDF) |
| 259 | Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525 | 1.0 | 18 | Citations (PDF) |
| 260 | Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases | 0.9 | 1 | Citations (PDF) |
| 261 | ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA) | 1.0 | 1 | Citations (PDF) |
| 262 | RTRB-14TREATMENT RECOMMENDATIONS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA LACK WORLDWIDE CONSENSUS | 1.0 | 0 | Citations (PDF) |
| 263 | Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424 | 1.5 | 153 | Citations (PDF) |
| 264 | Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review | 2.3 | 24 | Citations (PDF) |
| 265 | Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933 | 1.5 | 34 | Citations (PDF) |
| 266 | The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients | 1.0 | 26 | Citations (PDF) |
| 267 | Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study | 2.5 | 98 | Citations (PDF) |
| 268 | Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627) | 1.0 | 137 | Citations (PDF) |
| 269 | Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: A report from the Children's Oncology Group | 1.3 | 70 | Citations (PDF) |
| 270 | Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131 | 2.5 | 31 | Citations (PDF) |
| 271 | Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base | 1.5 | 0 | Citations (PDF) |
| 272 | What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases? | 2.5 | 18 | Citations (PDF) |
| 273 | CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933 | 2.5 | 35 | Citations (PDF) |
| 274 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study | 2.5 | 68 | Citations (PDF) |
| 275 | Management of solitary and multiple brain metastases from breast cancer | 0.4 | 21 | Citations (PDF) |
| 276 | Stereotactic Radiosurgery for Glioblastoma | 0.6 | 36 | Citations (PDF) |
| 277 | SU‐E‐T‐626: Practical Method to Implement Arc Therapy Using Scanned Particle Beams | 3.1 | 1 | Citations (PDF) |
| 278 | Radiation-induced brain damage, impact of Michael Robbins’ work and the need for predictive biomarkers | 2.2 | 17 | Citations (PDF) |
| 279 | Prophylactic Cranial Irradiation: Recent Outcomes and Innovations | 2.4 | 15 | Citations (PDF) |
| 280 | Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 | 1.0 | 149 | Citations (PDF) |
| 281 | P17.50 * PHASE II STUDY OF ARSENIC TRIOXIDE AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH MALIGNANT GLIOMAS | 1.0 | 0 | Citations (PDF) |
| 282 | BENEFICIAL OUTCOMES AFTER PCV PLUS RT IN OLIGODENDROGLIAL TUMORS ARE ASSOCIATED WITH DETECTION OR RISK OF AN IDH MUTATION | 1.0 | 0 | Citations (PDF) |
| 283 | Bevacizumab for Newly Diagnosed Glioblastoma | 34.6 | 99 | Citations (PDF) |
| 284 | O7.01 * RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES | 1.0 | 3 | Citations (PDF) |
| 285 | Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer | 1.3 | 17 | Citations (PDF) |
| 286 | Reirradiation for Locoregionally Recurrent Lung Cancer | 1.3 | 40 | Citations (PDF) |
| 287 | It Is Time to Reevaluate the Management of Patients With Brain Metastases | 2.0 | 27 | Citations (PDF) |
| 288 | A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma | 34.6 | 2,637 | Citations (PDF) |
| 289 | Potential of glyburide to reduce intracerebral edema in brain metastases | 2.9 | 10 | Citations (PDF) |
| 290 | Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA) | 1.5 | 166 | Citations (PDF) |
| 291 | Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation | 2.8 | 16 | Citations (PDF) |
| 292 | Application of a Survival-Predicting Nomogram Based Primarily on Whole-Brain Radiation Therapy–Treated Patients With Brain Metastases Yields Significant Underestimates for Radiosurgery-Treated Patients | 1.5 | 0 | Citations (PDF) |
| 293 | Brain metastasis and treatment | 4.1 | 52 | Citations (PDF) |
| 294 | BM-13 * THE (F)UTILITY OF PREDICTIVE MODELS | 1.0 | 1 | Citations (PDF) |
| 295 | PD-0517: Memory preservation in patients with brain metastases following hippocampal avoidance whole-brain RT | 2.0 | 0 | Citations (PDF) |
| 296 | AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE | 1.0 | 7 | Citations (PDF) |
| 297 | SU-E-T-387: Achieving Optimal Patient Setup Imaging and Treatment Workflow Configurations in Multi-Room Proton Centers | 3.1 | 0 | Citations (PDF) |
| 298 | The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer | 2.5 | 154 | Citations (PDF) |
| 299 | RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients | 1.5 | 154 | Citations (PDF) |
| 300 | Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial | 1.0 | 891 | Citations (PDF) |
| 301 | RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | 1.5 | 62 | Citations (PDF) |
| 302 | New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials | 1.0 | 100 | Citations (PDF) |
| 303 | Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group | 27.4 | 125 | Citations (PDF) |
| 304 | Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group | 27.4 | 134 | Citations (PDF) |
| 305 | An Evaluation of Worldwide Proton Beam Therapy Clinical Trials | 1.5 | 0 | Citations (PDF) |
| 306 | Cilengitide Inhibits Proliferation and Shows Combined Effects With Radiation in Breast Cancer Cell Lines | 1.5 | 1 | Citations (PDF) |
| 307 | Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors | 1.5 | 341 | Citations (PDF) |
| 308 | A Roundtable Discussion on the Clinical Challenges and Options for the Treatment of Glioblastoma: Introducing a Novel Modality, TTFields | 1.9 | 5 | Citations (PDF) |
| 309 | A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320 | 1.5 | 266 | Citations (PDF) |
| 310 | Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM) | 9.0 | 6 | Citations (PDF) |
| 311 | Pseudoprogression after glioma therapy: a comprehensive review | 2.9 | 107 | Citations (PDF) |
| 312 | Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine | 2.4 | 58 | Citations (PDF) |
| 313 | Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy | 4.6 | 41 | Citations (PDF) |
| 314 | American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS) | 1.3 | 108 | Citations (PDF) |
| 315 | Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report | 1.4 | 5 | Citations (PDF) |
| 316 | Elucidation of How Cancer Cells Avoid Acidosis through Comparative Transcriptomic Data Analysis | 2.3 | 25 | Citations (PDF) |
| 317 | Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery | 2.5 | 75 | Citations (PDF) |
| 318 | Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy 2013, 4, 59 | | 10 | Citations (PDF) |
| 319 | SU-E-T-241: Achieving Optimal Treatment Workflow Configurations in Multi-Room Proton Centers Via Monte Carlo Simulation | 3.1 | 0 | Citations (PDF) |
| 320 | Treatment of Wilmsʼ Tumour | 11.4 | 9 | Citations (PDF) |
| 321 | Brain metastases | 1.8 | 17 | Citations (PDF) |
| 322 | Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review | 2.5 | 17 | Citations (PDF) |
| 323 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 | 1.0 | 105 | Citations (PDF) |
| 324 | Integrated phase II/III clinical trials in oncology: A case study | 1.8 | 7 | Citations (PDF) |
| 325 | Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors | 25.2 | 334 | Citations (PDF) |
| 326 | A nomogram for individualized estimation of survival among patients with brain metastasis | 1.0 | 135 | Citations (PDF) |
| 327 | Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases | 1.5 | 360 | Citations (PDF) |
| 328 | Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors | 1.5 | 219 | Citations (PDF) |
| 329 | IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402) | 1.5 | 0 | Citations (PDF) |
| 330 | Phase 1 Study of Veliparib With Concurrent Whole Brain Radiation Therapy (WBRT) in Patients (PTS) With Brain Metastases (METS) | 10.0 | 0 | Citations (PDF) |
| 331 | Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiosurgery for patients with single intracranial metastases | 2.5 | 29 | Citations (PDF) |
| 332 | Brain metastases: pathobiology and emerging targeted therapies | 9.2 | 190 | Citations (PDF) |
| 333 | A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) | 2.5 | 15 | Citations (PDF) |
| 334 | A Comparative Study of Gene-Expression Data of Basal Cell Carcinoma and Melanoma Reveals New Insights about the Two Cancers | 2.3 | 23 | Citations (PDF) |
| 335 | Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer | 1.8 | 26 | Citations (PDF) |
| 336 | An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway | 25.2 | 414 | Citations (PDF) |
| 337 | Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma | 0.7 | 15 | Citations (PDF) |
| 338 | In response to “The distribution of brain metastases in the perihippocampal region (Regarding Gondi et al., Radiother. Oncol. 2010; 95: 327–331) by van Kesteren et al | 2.0 | 3 | Citations (PDF) |
| 339 | Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy | 2.0 | 160 | Citations (PDF) |
| 340 | Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma | 1.5 | 228 | Citations (PDF) |
| 341 | A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma | 1.5 | 29 | Citations (PDF) |
| 342 | Reply to Drs. Mulvenna and Holt | 1.5 | 0 | Citations (PDF) |
| 343 | Crimean-Congo haemorrhagic fever in India | 62.4 | 62 | Citations (PDF) |
| 344 | Combined Modality Approaches in the Management of Adult Glioblastoma | 2.6 | 8 | Citations (PDF) |
| 345 | Stereotactic Body Radiation Therapy in Non–Small-Cell Lung Cancer | 1.3 | 14 | Citations (PDF) |
| 346 | Temozolomide-induced severe myelosuppression | 1.3 | 21 | Citations (PDF) |
| 347 | A Comparison of Helical Tomotherapy to Circular Collimator-Based Linear-Accelerator Radiosurgery for the Treatment of Brain Metastases | 1.3 | 17 | Citations (PDF) |
| 348 | Early toxicity predicts long-term survival in high-grade glioma | 5.5 | 38 | Citations (PDF) |
| 349 | Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison | 2.5 | 44 | Citations (PDF) |
| 350 | Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤6 brain metastases: a multi-institutional phase II trial | 2.5 | 19 | Citations (PDF) |
| 351 | Presentation, patterns of care, and survival in patients with brain metastases | 4.0 | 184 | Citations (PDF) |
| 352 | In Response to Dr. Knisely and Colleagues | 1.5 | 1 | Citations (PDF) |
| 353 | Intensity-Modulated Radiotherapy Might Increase Pneumonitis Risk Relative to Three-Dimensional Conformal Radiotherapy in Patients Receiving Combined Chemotherapy and Radiotherapy: A Modeling Study of Dose Dumping | 1.5 | 32 | Citations (PDF) |
| 354 | Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? | 1.0 | 111 | Citations (PDF) |
| 355 | Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept | 6.8 | 63 | Citations (PDF) |
| 356 | Role of isocitrate dehydrogenase in glioma | 2.9 | 15 | Citations (PDF) |
| 357 | Clinical trial end points for high-grade glioma: the evolving landscape | 1.0 | 111 | Citations (PDF) |
| 358 | Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery | 2.5 | 122 | Citations (PDF) |
| 359 | Prognostic value of H-MLH1 after adjusting for RPA class in GBM patients | 1.9 | 2 | Citations (PDF) |
| 360 | Novel insights into the management of brain metastases | 3.8 | 19 | Citations (PDF) |
| 361 | Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402 | 1.5 | 53 | Citations (PDF) |
| 362 | On the Use of Hyperpolarized Helium MRI for Conformal Avoidance Lung Radiotherapy | 0.9 | 38 | Citations (PDF) |
| 363 | Fractionated radiotherapy for intracranial meningiomas | 2.5 | 22 | Citations (PDF) |
| 364 | Opportunities for clinical research in meningioma | 2.5 | 27 | Citations (PDF) |
| 365 | Angiogenic Blockade and Radiotherapy in Hepatocellular Carcinoma | 1.5 | 48 | Citations (PDF) |
| 366 | Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients | 1.5 | 947 | Citations (PDF) |
| 367 | Hippocampal-Sparing Whole-Brain Radiotherapy: A “How-To” Technique Using Helical Tomotherapy and Linear Accelerator–Based Intensity-Modulated Radiotherapy | 1.5 | 357 | Citations (PDF) |
| 368 | Treatment-Related Pneumonitis and Acute Esophagitis in Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy and Helical Tomotherapy: In Regard to Song et al. | 1.5 | 0 | Citations (PDF) |
| 369 | PROOF OF PRINCIPLE OF OCULAR SPARING IN DOGS WITH SINONASAL TUMORS TREATED WITH INTENSITY-MODULATED RADIATION THERAPY | 1.3 | 73 | Citations (PDF) |
| 370 | A multigene predictor of outcome in glioblastoma | 1.0 | 354 | Citations (PDF) |
| 371 | Current Treatment Strategies for Brain Metastasis and Complications From Therapeutic Techniques | 1.3 | 65 | Citations (PDF) |
| 372 | A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas | 1.0 | 49 | Citations (PDF) |
| 373 | Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) | 1.0 | 207 | Citations (PDF) |
| 374 | A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy | 1.0 | 268 | Citations (PDF) |
| 375 | Radiographic Pneumonitis Patterns and Low Pulmonary Toxicity After Helical Tomotherapy | 4.1 | 5 | Citations (PDF) |
| 376 | Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933 | 2.0 | 181 | Citations (PDF) |
| 377 | Why avoid the hippocampus? A comprehensive review | 2.0 | 369 | Citations (PDF) |
| 378 | Current practices of driving restriction implementation for patients with brain tumors | 2.5 | 23 | Citations (PDF) |
| 379 | Motexafin gadolinium: a novel radiosensitizer for brain tumors | 2.1 | 15 | Citations (PDF) |
| 380 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 | 1.0 | 56 | Citations (PDF) |
| 381 | The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study | 2.3 | 33 | Citations (PDF) |
| 382 | EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy | 5.4 | 320 | Citations (PDF) |
| 383 | On the Estimation of the Location of the Hippocampus in the Context of Hippocampal Avoidance Whole Brain Radiotherapy Treatment Planning | 2.3 | 12 | Citations (PDF) |
| 384 | Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) | 1.0 | 150 | Citations (PDF) |
| 385 | A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931) | 1.5 | 52 | Citations (PDF) |
| 386 | Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03 | 2.5 | 43 | Citations (PDF) |
| 387 | Prognostic indices for brain metastases – usefulness and challenges | 2.7 | 99 | Citations (PDF) |
| 388 | Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03 | 1.5 | 98 | Citations (PDF) |
| 389 | Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial | 1.5 | 169 | Citations (PDF) |
| 390 | Radiation Techniques in Neuro-Oncology | 6.1 | 15 | Citations (PDF) |
| 391 | Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients | 1.6 | 33 | Citations (PDF) |
| 392 | A Comprehensive Assessment by Tumor Site of Patient Setup Using Daily MVCT Imaging From More Than 3,800 Helical Tomotherapy Treatments | 1.5 | 93 | Citations (PDF) |
| 393 | Commissioning and Quality Assurance of RapidArc Radiotherapy Delivery System: In Regard to Ling et al. (Int J Radiat Oncol Biol Phys 2008;72;575–581): Absence of Data Does Not Constitute Proof; The Proof is in Tasting the Pudding | 1.5 | 18 | Citations (PDF) |
| 394 | The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 131 | Citations (PDF) |
| 395 | The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 133 | Citations (PDF) |
| 396 | The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 335 | Citations (PDF) |
| 397 | The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics | 2.5 | 49 | Citations (PDF) |
| 398 | The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 291 | Citations (PDF) |
| 399 | The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 390 | Citations (PDF) |
| 400 | The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 149 | Citations (PDF) |
| 401 | The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | 2.5 | 480 | Citations (PDF) |
| 402 | Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma | 2.5 | 189 | Citations (PDF) |
| 403 | Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults | 2.5 | 34 | Citations (PDF) |
| 404 | The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group | 2.7 | 46 | Citations (PDF) |
| 405 | In Reply to Drs. Nieder and Molls | 1.5 | 0 | Citations (PDF) |
| 406 | A Multi-institutional Validation Study of a New Prognostic Index (Graded Prognostic Assessment, GPA) for Patients with Brain Metastases | 1.5 | 4 | Citations (PDF) |
| 407 | Dose Coverage Beyond the Gross Tumor Volume for Various Stereotactic Body Radiotherapy Planning Techniques Reporting Similar Control Rates for Stage I Non–Small-Cell Lung Cancer | 1.5 | 22 | Citations (PDF) |
| 408 | Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118 | 1.5 | 88 | Citations (PDF) |
| 409 | A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118) | 1.5 | 93 | Citations (PDF) |
| 410 | Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis | 1.5 | 277 | Citations (PDF) |
| 411 | In Reply to Drs. Weltman and Brandt | 1.5 | 0 | Citations (PDF) |
| 412 | Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 | 5.0 | 127 | Citations (PDF) |
| 413 | A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database | 1.5 | 982 | Citations (PDF) |
| 414 | Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity | 16.9 | 782 | Citations (PDF) |
| 415 | Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study | 2.3 | 65 | Citations (PDF) |
| 416 | Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas | 1.0 | 394 | Citations (PDF) |
| 417 | Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium | 1.0 | 30 | Citations (PDF) |
| 418 | The impact of linac output variations on dose distributions in helical tomotherapy | 3.1 | 19 | Citations (PDF) |
| 419 | Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study | 1.0 | 50 | Citations (PDF) |
| 420 | Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma | 1.3 | 101 | Citations (PDF) |
| 421 | A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas | 2.5 | 75 | Citations (PDF) |
| 422 | MO-E-AUD C-03: Use of FLT-PET Imaging to Assess Tumor and Normal Tissue Response to Radiotherapy | 3.1 | 0 | Citations (PDF) |
| 423 | Resection versus radiosurgery for patients with brain metastases | 2.3 | 12 | Citations (PDF) |
| 424 | Motexafin gadolinium: a novel radiosensitizer for brain tumors | 2.5 | 24 | Citations (PDF) |
| 425 | In Reply | 16.9 | 3 | Citations (PDF) |
| 426 | Megavoltage Computed Tomography | 1.3 | 31 | Citations (PDF) |
| 427 | In Reply | 16.9 | 2 | Citations (PDF) |
| 428 | Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function | 16.9 | 322 | Citations (PDF) |
| 429 | Motexafin gadolinium in the treatment of brain metastases | 2.1 | 31 | Citations (PDF) |
| 430 | Advances in Radiation Therapy for Brain Tumors | 2.6 | 27 | Citations (PDF) |
| 431 | Therapeutic management of metastatic brain tumors | 5.0 | 39 | Citations (PDF) |
| 432 | Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non–small-cell lung cancer | 1.5 | 93 | Citations (PDF) |
| 433 | Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119) | 1.5 | 51 | Citations (PDF) |
| 434 | Distribution of Brain Metastases in Relation to the Hippocampus: Implications for Neurocognitive Functional Preservation | 1.5 | 183 | Citations (PDF) |
| 435 | Breathing-Synchronized Delivery: A Potential Four-Dimensional Tomotherapy Treatment Technique | 1.5 | 26 | Citations (PDF) |
| 436 | Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme | 1.5 | 43 | Citations (PDF) |
| 437 | Whole Brain Radiotherapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost: A Planning Study | 1.5 | 183 | Citations (PDF) |
| 438 | Neurocognitive Impact of Whole Brain Radiation on Patients With Brain Metastases: Secondary Analysis of RTOG BR-0018 | 1.5 | 3 | Citations (PDF) |
| 439 | Whole Brain Radiation Therapy With Hippocampal Avoidance and Simultaneously Integrated Brain Metastases Boost With Helical Tomotherapy: A Planning Study | 1.5 | 3 | Citations (PDF) |
| 440 | Therapeutic advances for glioblastoma multiforme: Current status and future prospects | 4.2 | 49 | Citations (PDF) |
| 441 | Impact of molecular profiling on clinical trial design for glioblastoma | 4.2 | 9 | Citations (PDF) |
| 442 | Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial | 2.1 | 56 | Citations (PDF) |
| 443 | TH-E-M100J-05: Early Assessment of Radiotherapy Efficacy with FLT-PET Imaging | 3.1 | 0 | Citations (PDF) |
| 444 | Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors | 2.0 | 55 | Citations (PDF) |
| 445 | Whole-Brain Radiotherapy in the Management of Brain Metastasis | 16.9 | 454 | Citations (PDF) |
| 446 | Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 | 16.9 | 697 | Citations (PDF) |
| 447 | Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer | 2.1 | 6 | Citations (PDF) |
| 448 | Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? | 5.0 | 32 | Citations (PDF) |
| 449 | Integral radiation dose to normal structures with conformal external beam radiation | 1.5 | 159 | Citations (PDF) |
| 450 | Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (Int J Radiat Oncol Biol Phys 2005;62:1549–1558) | 1.5 | 7 | Citations (PDF) |
| 451 | A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023 | 1.5 | 98 | Citations (PDF) |
| 452 | Tumor volume changes on serial imaging with megavoltage CT for non–small-cell lung cancer during intensity-modulated radiotherapy: How reliable, consistent, and meaningful is the effect? | 1.5 | 111 | Citations (PDF) |
| 453 | In response to Dr. Peñagarícano | 1.5 | 1 | Citations (PDF) |
| 454 | Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-β for supratentorial glioblastoma: Results of RTOG 9710 | 1.5 | 52 | Citations (PDF) |
| 455 | Tomotherapy and Other Innovative IMRT Delivery Systems | 2.7 | 74 | Citations (PDF) |
| 456 | Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation | 1.8 | 73 | Citations (PDF) |
| 457 | A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1 | 1.0 | 210 | Citations (PDF) |
| 458 | Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy | 2.3 | 87 | Citations (PDF) |
| 459 | Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study | 16.9 | 153 | Citations (PDF) |
| 460 | Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model | 16.9 | 584 | Citations (PDF) |
| 461 | Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211 | 1.0 | 57 | Citations (PDF) |
| 462 | Linear Accelerator Radiosurgery for Trigeminal Neuralgia | 2.0 | 48 | Citations (PDF) |
| 463 | The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy | 1.5 | 265 | Citations (PDF) |
| 464 | Accelerated hypofractionation | 1.5 | 3 | Citations (PDF) |
| 465 | Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group | 1.5 | 47 | Citations (PDF) |
| 466 | In response to Drs. Vordermark and Kölbl | 1.5 | 0 | Citations (PDF) |
| 467 | In reply to Dr. Kondziolka et al | 1.5 | 2 | Citations (PDF) |
| 468 | The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases | 1.5 | 336 | Citations (PDF) |
| 469 | The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma | 1.5 | 167 | Citations (PDF) |
| 470 | Health-Related Quality of Life and Cognitive Status in Patients with Glioblastoma Multiforme Receiving Escalating Doses of Conformal Three-Dimensional Radiation on RTOG 9803 | 1.5 | 0 | Citations (PDF) |
| 471 | Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment? | 1.9 | 9 | Citations (PDF) |
| 472 | Potential for Radiation Therapy Technology Innovations to Permit Dose Escalation for Non–Small-Cell Lung Cancer | 2.8 | 13 | Citations (PDF) |
| 473 | Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas | 4.0 | 37 | Citations (PDF) |
| 474 | A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas | 4.0 | 51 | Citations (PDF) |
| 475 | Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma | 2.5 | 92 | Citations (PDF) |
| 476 | Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study | 1.3 | 19 | Citations (PDF) |
| 477 | Current Strategies in Whole-brain Radiation Therapy for Brain Metastases | 2.0 | 42 | Citations (PDF) |
| 478 | Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397) | 16.9 | 182 | Citations (PDF) |
| 479 | Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non–Small-Cell Lung Cancer | 16.9 | 152 | Citations (PDF) |
| 480 | Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study | 16.9 | 62 | Citations (PDF) |
| 481 | Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? | 1.5 | 66 | Citations (PDF) |
| 482 | Strategies for enhanced radiation delivery in patients with lung cancer | 5.0 | 3 | Citations (PDF) |
| 483 | Current Management of Brain Metastases, With a Focus on Systemic Options | 16.9 | 360 | Citations (PDF) |
| 484 | Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study | 16.9 | 84 | Citations (PDF) |
| 485 | Helical Tomotherapy as a Means of Delivering Accelerated Partial Breast Irradiation | 2.3 | 41 | Citations (PDF) |
| 486 | The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme | 2.3 | 39 | Citations (PDF) |
| 487 | Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant
glioma: A North American Brain Tumor Consortium study | 1.0 | 77 | Citations (PDF) |
| 488 | Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial | 16.9 | 564 | Citations (PDF) |
| 489 | Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents | 2.9 | 19 | Citations (PDF) |
| 490 | Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade
astrocytomas using fluorescence in situ hybridization on tissue microarrays
from Radiation Therapy Oncology Group trials | 1.0 | 56 | Citations (PDF) |
| 491 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma
multiforme: North American Brain Tumor Consortium study | 1.0 | 58 | Citations (PDF) |
| 492 | O
6-Benzylguanine suppression of
O6-alkylguanine-DNA alkyltransferase in anaplastic
gliomas | 1.0 | 33 | Citations (PDF) |
| 493 | Management of brain metastases | 1.9 | 107 | Citations (PDF) |
| 494 | Megavoltage Computed Tomography Imaging: A Potential Tool to Guide and Improve the Delivery of Thoracic Radiation Therapy | 2.8 | 48 | Citations (PDF) |
| 495 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors | 1.5 | 18 | Citations (PDF) |
| 496 | Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study | 1.5 | 32 | Citations (PDF) |
| 497 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma | 4.0 | 52 | Citations (PDF) |
| 498 | Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018 | 1.5 | 83 | Citations (PDF) |
| 499 | The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data | 1.5 | 124 | Citations (PDF) |
| 500 | Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study | 1.5 | 18 | Citations (PDF) |
| 501 | Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol | 1.5 | 567 | Citations (PDF) |
| 502 | A challenge to traditional radiation oncology | 1.5 | 285 | Citations (PDF) |
| 503 | American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy | 1.5 | 198 | Citations (PDF) |
| 504 | The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes | 1.5 | 140 | Citations (PDF) |
| 505 | Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations | 2.0 | 17 | Citations (PDF) |
| 506 | A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies | 2.6 | 6 | Citations (PDF) |
| 507 | Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial | 62.4 | 2,375 | Citations (PDF) |
| 508 | Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018 | 1.5 | 0 | Citations (PDF) |
| 509 | Title is missing! | 2.5 | 6 | Citations (PDF) |
| 510 | Combined modality treatment for central nervous system malignancies | 1.9 | 16 | Citations (PDF) |
| 511 | Image guidance for precise conformal radiotherapy | 1.5 | 456 | Citations (PDF) |
| 512 | Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients | 1.5 | 41 | Citations (PDF) |
| 513 | Craniospinal treatment with the patient supine | 0.9 | 23 | Citations (PDF) |
| 514 | Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors | 2.7 | 20 | Citations (PDF) |
| 515 | P-465 Differences in baseline characteristics between non-small cell lung cancer (NSCLC) and breast cancer (BrCa) patients with brain metastases | 2.6 | 0 | Citations (PDF) |
| 516 | Cancer in the Nervous System, Second Edition | 1.0 | 0 | Citations (PDF) |
| 517 | Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394 | 16.9 | 135 | Citations (PDF) |
| 518 | RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database | 16.9 | 101 | Citations (PDF) |
| 519 | Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases | 16.9 | 457 | Citations (PDF) |
| 520 | Controversies in Neuro-Oncology. Frontiers of Radiation Therapy and
Oncology, Volume 33 | 1.0 | 0 | Citations (PDF) |
| 521 | Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study | 16.9 | 153 | Citations (PDF) |
| 522 | Gentlemen (and Ladies), Choose your Weapons: Gamma Knife vs. Linear Accelerator Radiosurgery | 2.3 | 37 | Citations (PDF) |
| 523 | A phase I study of topotecan as a radiosensitizer for brainstem glioma of
childhood: First report of the Children's Cancer Group-0952 | 1.0 | 41 | Citations (PDF) |
| 524 | Reduction in Radiation Dose to Lung and Other Normal Tissues Using Helical Tomotherapy to Treat Lung Cancer, in Comparison to Conventional Field Arrangements | 1.3 | 81 | Citations (PDF) |
| 525 | Title is missing! | 1.3 | 13 | Citations (PDF) |
| 526 | Neurocognitive and Functional Assessment of Patients With Brain Metastases | 1.3 | 71 | Citations (PDF) |
| 527 | Mapping of physiological and trace elements with X-PEEM | 0.3 | 7 | Citations (PDF) |
| 528 | Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy | 2.3 | 159 | Citations (PDF) |
| 529 | Fractionated Stereotactic Radiotherapy: A Short Review | 2.3 | 26 | Citations (PDF) |
| 530 | Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points | 16.9 | 143 | Citations (PDF) |
| 531 | A phase II trial of thymidine and carboplatin for recurrent malignant
glioma: A North American Brain Tumor Consortium Study | 1.0 | 47 | Citations (PDF) |
| 532 | Trastuzumab for Breast Cancer–Related Carcinomatous Meningitis | 2.3 | 17 | Citations (PDF) |
| 533 | Three-dimensional conformal radiotherapy for lung cancer: Promises and pitfalls | 4.2 | 10 | Citations (PDF) |
| 534 | Pineal Sarcoma | 1.5 | 4 | Citations (PDF) |
| 535 | Retrospective vs. randomized data: the prevalence of bias. in response to Drs. Millar and Laperriere | 1.5 | 0 | Citations (PDF) |
| 536 | A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases | 1.5 | 522 | Citations (PDF) |
| 537 | What is the appropriate primary end point for clinical trials for patients with brain metastases? In Response to Drs. Burri and Asher | 1.5 | 4 | Citations (PDF) |
| 538 | Optically guided intensity modulated radiotherapy | 2.0 | 45 | Citations (PDF) |
| 539 | Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases | 16.9 | 128 | Citations (PDF) |
| 540 | Multiple daily fractionation radiotherapy schedules in lung cancer | 4.2 | 4 | Citations (PDF) |
| 541 | A new approach to dose escalation in non–small-cell lung cancer | 1.5 | 243 | Citations (PDF) |
| 542 | Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593 | 1.5 | 37 | Citations (PDF) |
| 543 | Gating-by-rotation: a solution to the problem of intratreatment motion in helical tomotherapy | 1.5 | 3 | Citations (PDF) |
| 544 | A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants | 4.0 | 97 | Citations (PDF) |
| 545 | Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy | 4.3 | 15 | Citations (PDF) |
| 546 | Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method | 1.5 | 267 | Citations (PDF) |
| 547 | Title is missing! | 0.1 | 0 | Citations (PDF) |
| 548 | Title is missing! | 2.5 | 34 | Citations (PDF) |
| 549 | Radiotherapy for brain tumors | 4.2 | 13 | Citations (PDF) |
| 550 | The Contemporary Role of Radiation Therapy in the Management of Lung Cancer | 1.5 | 4 | Citations (PDF) |
| 551 | A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus
temozolomide: A North American Brain Tumor Consortium study | 1.0 | 27 | Citations (PDF) |
| 552 | Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer | 2.8 | 25 | Citations (PDF) |
| 553 | Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report | 16.9 | 71 | Citations (PDF) |
| 554 | Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer | 16.9 | 7 | Citations (PDF) |
| 555 | Radiosurgery for Brain Metastases | 1.4 | 35 | Citations (PDF) |
| 556 | 27 The role of the MAPK signaling pathway in expression of the pro-apoptotic protein, PQR/TDAG51, in differentiating neuronal cells vs irradiated primitive neuroectodermal tumor cells | 1.5 | 0 | Citations (PDF) |
| 557 | Title is missing! | 0.1 | 13 | Citations (PDF) |
| 558 | Title is missing! | 0.1 | 3 | Citations (PDF) |
| 559 | Tomotherapy | 2.7 | 403 | Citations (PDF) |
| 560 | Development of a Unique Phantom to Assess the Geometric Accuracy of Magnetic Resonance Imaging for Stereotactic Localization | 2.0 | 69 | Citations (PDF) |
| 561 | Stereotactic Irradiation | 1.3 | 27 | Citations (PDF) |
| 562 | The Status of Stereotactic Radiosurgery for Cerebral Metastases in 1998 | 0.1 | 11 | Citations (PDF) |
| 563 | On “Stereotactic Radiosurgery for Patients with Single Brain Metastasis” (Cho et al., This Issue) | 0.1 | 0 | Citations (PDF) |
| 564 | An Analysis of Postradiosurgery Histopathology with Dose, Time, and Radiographic Correlation and Implications for Dose Prescription | 0.1 | 2 | Citations (PDF) |
| 565 | Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions | 1.5 | 0 | Citations (PDF) |
| 566 | Comparison of methods for response analysis of central nervous system neoplasms | 1.5 | 1 | Citations (PDF) |
| 567 | Topotecan, as a radiosensitizer, for brainstem glioma (BSG) of childhood: First report of CCG 0952, a phase i study | 1.5 | 2 | Citations (PDF) |
| 568 | Principles and Practice of Radiation Therapy: Introduction to Radiation Therapy
, by Charles M. Washington and Dennis T. Leaver | 3.1 | 0 | Citations (PDF) |
| 569 | A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases | 1.5 | 200 | Citations (PDF) |
| 570 | Title is missing! | 2.5 | 54 | Citations (PDF) |
| 571 | The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population | 1.5 | 41 | Citations (PDF) |
| 572 | 214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions | 1.5 | 0 | Citations (PDF) |
| 573 | 19 Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high risk intracranial primitive neuroectodermal tumors (HRPNET); CCG-9931; A groupwide phase II study of intensive chemotherapy (CT) & CHFRT | 1.5 | 0 | Citations (PDF) |
| 574 | 1021 Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, fundoscopy and histology | 1.5 | 0 | Citations (PDF) |
| 575 | 1034 Experience with the functional assessment of cancer therapy-lung (FACT-L) in ecog 4593, a phase II hyperfractionated accelerated radiation therapy (HART) trial | 1.5 | 0 | Citations (PDF) |
| 576 | Thorotrast-associated Oropharyngeal Hemorrhage: Treatment by Means of Carotid Occlusion with Use of Flow Arrest and Fibered Coils | 1.1 | 4 | Citations (PDF) |
| 577 | Localized 2DJ-resolved H MR spectroscopy of human brain tumorsin vivo | 3.4 | 91 | Citations (PDF) |
| 578 | Manpower issues and training program directions in radiation oncology | 1.5 | 0 | Citations (PDF) |
| 579 | A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis | 1.5 | 525 | Citations (PDF) |
| 580 | 214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions | 1.5 | 0 | Citations (PDF) |
| 581 | 98 A multi-institutional phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Initial report of ECOG 4593 | 1.5 | 2 | Citations (PDF) |
| 582 | The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation | 2.5 | 49 | Citations (PDF) |
| 583 | Linear accelerator configurations for radiosurgery | 2.7 | 17 | Citations (PDF) |
| 584 | The physical, biologic, and clinical basis of radiosurgery | 2.0 | 34 | Citations (PDF) |
| 585 | Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis | 1.5 | 178 | Citations (PDF) |
| 586 | 83 Patterns of failure in CCG 921, a phase III study of chemoradiotherapy in high-risk intracranial PNET | 1.5 | 0 | Citations (PDF) |
| 587 | 110 Phase II clinical trial of amifostine (WR2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable stage III non small cell lung cancer (NSCLC). | 1.5 | 3 | Citations (PDF) |
| 588 | 2047 Definition of AVM nidus for radiosurgery using segmentation tools | 1.5 | 0 | Citations (PDF) |
| 589 | Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis | 1.5 | 7 | Citations (PDF) |
| 590 | Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage | 1.5 | 151 | Citations (PDF) |
| 591 | Current radiosurgery practice: results of an astro survey | 1.5 | 50 | Citations (PDF) |
| 592 | Consensus statement on stereotactic radiosurgery quality improvement | 1.5 | 26 | Citations (PDF) |
| 593 | Cost comparison of radiosurgery and surgery for treatment of brain metastasis | 1.5 | 0 | Citations (PDF) |
| 594 | Thoracic volume radiation sparing following endobronchial brachytherapy: A quantitative analysis | 1.5 | 23 | Citations (PDF) |
| 595 | Treatment of arteriovenous malformations with stereotactic radiosurgery employing both magnetic resonance angiography and standard angiography as a database | 1.5 | 55 | Citations (PDF) |
| 596 | Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used | 1.5 | 80 | Citations (PDF) |
| 597 | Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors* | 1.5 | 53 | Citations (PDF) |
| 598 | Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost | 1.5 | 0 | Citations (PDF) |
| 599 | Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme | 2.5 | 37 | Citations (PDF) |
| 600 | Correlation of post-radiosurgical histopathology with radiographic changes | 1.5 | 1 | Citations (PDF) |
| 601 | A Retrospective Review of Nodal Treatment for Vulvar Cancer | 1.3 | 40 | Citations (PDF) |
| 602 | RELATIVE PRE- AND POSTJUNCTIONAL EFFECTS OF A NEW VECURONIUM ANALOGUE, ORG 9426, AT THE RAT NEUROMUSCULAR JUNCTION | 4.9 | 13 | Citations (PDF) |
| 603 | Weight Consideration in the Use of Cerrobend Beam Blocks | 0.9 | 2 | Citations (PDF) |
| 604 | Meningeal hemangiopericytoma: defining the role for radiation therapy | 2.5 | 72 | Citations (PDF) |
| 605 | Is inguino-femoral irradiation as effective as lymphadenectomy for N0, N1 vulvar disease? | 1.5 | 1 | Citations (PDF) |
| 606 | Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion | 1.5 | 64 | Citations (PDF) |
| 607 | Endobronchial brachytherapy: Wither prescription point | 1.5 | 1 | Citations (PDF) |
| 608 | Defining the role of radiosurgery in the management of brain metastases | 1.5 | 284 | Citations (PDF) |
| 609 | The role of magnetic resonance angiography in the radiosurgical management of arteriovenous malformations | 1.5 | 1 | Citations (PDF) |
| 610 | A three-dimensional volume visualization package applied to stereotactic radiosurgery treatment planning | 1.5 | 46 | Citations (PDF) |
| 611 | Early changes in tumor metabolism after treatment: The effects of stereotactic radiotherapy | 1.5 | 60 | Citations (PDF) |
| 612 | Sequential comparison of ldr and hyperfractionated HDR EBRT for MAO | 1.5 | 333 | Citations (PDF) |
| 613 | Radiosurgery for brain metastases | 1.5 | 2 | Citations (PDF) |
| 614 | Effect of Endobronchial Radiation Therapy on Malignant Bronchial Obstruction | 1.0 | 46 | Citations (PDF) |
| 615 | Technical Aspects in the Use of “Belly Boards” for Small Bowel Minimization | 0.9 | 8 | Citations (PDF) |
| 616 | Monte Carlo and convolution dosimetry for stereotactic radiosurgery | 1.5 | 49 | Citations (PDF) |
| 617 | Conventional vs. hyperfractionated high dose rate endobronchial radiation | 1.5 | 0 | Citations (PDF) |
| 618 | 90Y · B72.3 Against pancreatic cancer: Dosimetric and biological analysis | 1.5 | 11 | Citations (PDF) |
| 619 | Minimization of small bowel volume within treatment fields utilizing customized “belly boards” | 1.5 | 103 | Citations (PDF) |
| 620 | Stereotactic radiation: Evaluation of brain tumor response | 1.5 | 3 | Citations (PDF) |
| 621 | Endobronchial irradiation for malignant airway obstruction | 1.5 | 60 | Citations (PDF) |
| 622 | Radioimmunotherapy: dosimetric and biological analysis | 1.5 | 0 | Citations (PDF) |
| 623 | An improved ray casting technique for surface-shaded display: applications in radiation treatment planning | 1.5 | 1 | Citations (PDF) |
| 624 | Minimization of small bowel volume utilizing customized “Belly Board” mold | 1.5 | 5 | Citations (PDF) |
| 625 | Monte Carlo and convolution dosimetry for stereotactic radiosurgery | 1.5 | 0 | Citations (PDF) |
| 626 | Direct computerized tomographic (CT) dosimetry of endobronchial implants | 1.5 | 1 | Citations (PDF) |
| 627 | Radiation induced thyroid neoplasms 1920 to 1987: A vanishing problem? | 1.5 | 33 | Citations (PDF) |
| 628 | Adult Wilms' Tumor: Role of Combined Modality Treatment | 1.8 | 4 | Citations (PDF) |
| 629 | Treatment of Probable Subclinical Liver Metastases and Gross Pancreatic Carcinoma with Hepatic Artery 5-Fluorouracil Infusion and Radiation Therapy | 1.8 | 13 | Citations (PDF) |
| 630 | An analysis of critical incidents in a teaching department for quality assurance A survey of mishaps during anaesthesia | 4.4 | 82 | Citations (PDF) |
| 631 | Accelerated Onset with Pancuronium, Atracurium, and Vecuronium: Comparison with Suxamethonium | 4.9 | 0 | Citations (PDF) |
| 632 | Malignant Paraganglioma of the Prostate and Retroperitoneum | 4.2 | 20 | Citations (PDF) |
| 633 | Barriers to accrual and enrollment in brain tumor trials | 1.0 | 50 | Citations (PDF) |
| 634 | Title is missing! 0 | | 1 | Citations (PDF) |
| 635 | Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design | 1.0 | 19 | Citations (PDF) |
| 636 | Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report | 1.0 | 6 | Citations (PDF) |
| 637 | Unraveling the effects of radiotherapy on the blood-brain barrier: Fact or fiction? | 1.0 | 0 | Citations (PDF) |
| 638 | Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions | 1.0 | 16 | Citations (PDF) |
| 639 | Initial three‐ and half‐year machine performance assessment of a superficial radiation therapy unit | 2.1 | 0 | Citations (PDF) |
| 640 | Importance of 3D-TSE imaging for patients with brain metastasis treated with SRS alone | 2.0 | 0 | Citations (PDF) |
| 641 | Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative | 1.0 | 1 | Citations (PDF) |
| 642 | Benchmarking Modern Day Pencil Beam Scanning Proton Therapy Treatment Times: Insights From Real Time Location Service Treatment Time Data | 1.9 | 0 | Citations (PDF) |
| 643 | Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for painful spine metastasis: A phase 2 randomized controlled trial | 1.0 | 0 | Citations (PDF) |
| 644 | Redefining neurocognitive outcomes after radiation for brain metastases: a patient-level meta-analysis of recovery following initial decline | 4.6 | 2 | Citations (PDF) |
| 645 | Evaluating the efficacy of a federated AI algorithm in assisting in the detection and segmentation of brain metastases: limitations and opportunities | 2.5 | 0 | Citations (PDF) |
| 646 | Quantifying risk of radiation necrosis: Normal tissue complication probability modeling following stereotactic radiosurgery for small brain metastases in the modern era | 2.0 | 2 | Citations (PDF) |
| 647 | Neurocognitive outcomes in patients with brain metastases: a systematic review | 27.4 | 1 | Citations (PDF) |
| 648 | MODELLING INTERNAL TARGET ORGAN DISPLACEMENT AND EXTERNAL TISSUE DIFFERENCES FOR PROSTATE CANCER WITH POSITIVE NODES TREATED USING IMAGE-GUIDED PROTON THERAPY | 1.9 | 0 | Citations (PDF) |
| 649 | DOSE-ESCALATED INTENSITY MODULATED PROTON THERAPY (IMPT) FOR POST-PROSTATECTOMY NODE-POSITIVE PROSTATE CANCER | 1.9 | 0 | Citations (PDF) |
| 650 | DOSIMETRIC INVESTIGATION OF BEAM DELIVERY METHODS FOR TEMPORALLY MODULATED PULSED PROTON RADIOTHERAPY | 1.9 | 0 | Citations (PDF) |
| 651 | OCCURRENCE OF RADIATION-INDUCED CEREBRAL CONTRAST ENHANCEMENT POST INTENSITY MODULATED PROTON THERAPY: EVALUATION OF THE EFFECT OF DOSE, LET, AND LOCATION | 1.9 | 0 | Citations (PDF) |
| 652 | EVALUATING FACTORS ASSOCIATED WITH LYMPHOPENIA IN LUNG CANCER PATIENTS TREATED WITH PROTON THERAPY | 1.9 | 0 | Citations (PDF) |
| 653 | Impact of Quality Improvement Interventions on the Efficiency of Treatment Planning Timelines in a Modern Proton Therapy Clinic | 1.3 | 0 | Citations (PDF) |
| 654 | Future Directions and Emerging Approaches in the Treatment of Brain Metastases | 1.8 | 0 | Citations (PDF) |
| 655 | In Reply to Skakodub et al | 1.5 | 0 | Citations (PDF) |
| 656 | PROG 85-26: Three decades of effort, a lesson in patience | 1.0 | 0 | Citations (PDF) |
| 657 | An initial comparative study of discretearc, dynamicarc, and intensity-modulated proton therapy techniques in head and neck cancer | 1.9 | 0 | Citations (PDF) |
| 658 | A retrospective FLASH planning study evaluating the impact of variable RBE models on conformal FLASH dose distributions | 1.9 | 0 | Citations (PDF) |
| 659 | From Concept to Clinic: Development and Prototype Implementation of the Intelligent Radiotherapy Collaboration System for Integrated Radiopharmaceutical Workflows | 1.5 | 0 | Citations (PDF) |
